SCHEMBL3168786

SCHEMBL3168786

O=C(O)C(O)(c1ccc(Cl)c(Cl)c1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.50
TSHR P16473 2/20 0.50
CYP2D6 P10635 1/20 0.50
HIF1A Q16665 1/20 0.50
CYP19A1 P11511 1/20 0.44
SRD5A2 P31213 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
EPHX1 P07099 1/20 0.39
EPHX2 P34913 1/20 0.39
HSD17B10 Q99714 1/20 0.38
SSTR4 P31391 1/20 0.38
KIF11 P52732 2/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
FDPS P14324 1/20 0.37
KMO O15229 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromomethane SCHEMBL3163376 0.94 CYP2C9 (0.50) CYP2C9TSHRCYP2D6HIF1ACYP19A1
SCHEMBL10817500 0.83 TSHR (0.50) CYP2C9TSHRCYP2D6HIF1ACYP19A1
SCHEMBL3173667 0.82 CYP2C9 (0.46) CYP2C9TSHRCYP2D6HIF1ANPC1
SCHEMBL3179071 0.82 CYP2C9 (0.46) CYP2C9TSHRCYP2D6HIF1ANPC1
SCHEMBL2348384 0.80 TSHR (0.47) CYP2C9TSHRCYP2D6HIF1ACYP19A1
Bromomethane SCHEMBL3169191 0.78 CYP2C9 (0.46) CYP2C9TSHRCYP2D6HIF1ANPC1
Bromomethane SCHEMBL3178733 0.78 CYP2C9 (0.46) CYP2C9CYP2D6HIF1AKMO
SCHEMBL1626481 0.78 AKR1C3 (0.51) TSHRCYP19A1SRD5A2NPC1RAB9A
SCHEMBL1774639 0.78 TSHR (0.48) TSHRCYP19A1SRD5A2NPC1RAB9A
SCHEMBL3170901 0.77 SMN1; SMN2 (0.47) TSHREPHX1EPHX2SSTR4HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1328524-B1 NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2012-12-12 EP disclosed
US-7652138-B2 Anticholinergics, processes for preparing them and pharmaceutical composition containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-01-26 US disclosed
US-20050054664-A1 Anticholinergics, processes for preparing them and pharmaceutical composition containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed
US-6852728-B2 Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-02-08 US disclosed
EP-1328524-A2 NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-07-23 EP disclosed
US-20020119991-A1 Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-08-29 US disclosed
WO-2002032898-A2 NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119991-A1 Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them CHRM1, CHRM3, CHRM2 CYP2C9 368/4885TSHR 839/4885CYP2D6 162/4885
US-20050054664-A1 Anticholinergics, processes for preparing them and pharmaceutical composition containing them CHRM1, CHRM3, CHRM2 CYP2C9 162/4885TSHR 453/4885CYP2D6 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.